Iconovo AB (publ) (STO:ICO)

Market Cap	115.41M +19.2%
Revenue (ttm)	2.42M +52.5%
Net Income	-37.24M
EPS	-0.46
Shares Out	96.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,581
Open	1.200
Previous Close	1.245
Day's Range	1.200 - 1.250
52-Week Range	0.870 - 1.820
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About Iconovo AB

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2013
• Employees: 12
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ICO

Financial Performance

In 2025, Iconovo AB's revenue was 1.10 million, a decrease of -62.35% compared to the previous year's 2.93 million. Losses were -43.36 million, 5.41% more than in 2024.

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 4, 2026

Data Sources Report a data error